Pharnext’s lead PLEODRUG © for treatment of CMT1

by | Nov 9, 2017 | 5 comments

The Hereditary Neuropathy Foundation (HNF) is a staunch champion for accurate and early Charcot-Marie-Tooth (CMT) disease diagnosis, recognizing its critical importance for patient care, research and treatments. For those with CMT and suffering with its progressive muscle atrophy and weakness in their legs, feet, arms and hands, there are currently no cures nor approved curative or symptomatic medications.

A change is on the horizon, though!

In December 2016, Pharnext, a French biopharmaceutical company, completed patient enrollment for the international Phase 3 clinical trial of PXT3003, Pharnext’s lead PLEODRUG ©, for treatment of CMT1A (the most common form of CMT). The trial’s primary endpoint is the change in the Overall Neuropathy Limitation Score (ONLS) to determine improvement of patient’s disability after 12 and 15 months of treatment.The trial results are expected in the second half of 2018.

HNF has been partnering with Pharnext to encourage this clinical trial’s development, and we want to thank all who are involved with the study, from the researchers and developers at Pharnext, the clinicians in the field and at our HNF-designated Centers of Excellence, to the patient-participants; all contribute and play a critical role.

HNF has been pleased to contribute to this groundbreaking research by providing U.S. clinical site identification and patient recruitment support for this pivotal Phase 3 trial of PXT3003. HNF resources such as the Global Registry for Inherited Neuropathies (GRIN), our online Inspire Patient Community and our CMT-Connect local patient empowerment programs have been instrumental. We are enthusiastic that our joint effort with Pharnext could result in the first ever therapy for CMT, and we look forward to continuing our collaboration to tackle the more rare forms of CMT in the future.

We can’t rest on our laurels, though!

It will take many, many clinical trials to build the pipeline of potential therapeutics necessary to serve the diverse needs of the entire CMT community. That is why we have created the Clinical Trial Support fund, specifically to raise the money for the clinical trials desperately needed by our patients. Your tax deductible donation will ensure that HNF can continue to support clinical trials for years to come.


Learn more on this topic

Related Blog Posts

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Targeting PMP22 in CMT1A Patients with Gene Duplication

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

Join the conversation

Leave a Comment


  1. Elsadig Ahmed

    This disease is found in the three sons — Have you discovered a cure for it

    • Estela Lugo

      Hello Elsadig,

      We are working tirelessly towards research and clinical trials towards effective treatments. At this time there is no cure for CMT.

  2. Sherry Weatherly

    It i s wonderful to hear there may be a treatment that works! I have CMT1A, my sister has it, my mother had it, all 3 of my children show signs of it already. I’d be thrilled if there was something we could to to stop it from getting worse, or help us to improve! Do keep us informed!

  3. Ronald Riskevich

    I have Charcot-Marie-Tooth, When will Clinical Trials be concluded? What is the time frame for FDA approval?


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news